163 related articles for article (PubMed ID: 2012769)
1. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin.
Bowen D; Culligan D; Jacobs A
Br J Haematol; 1991 Mar; 77(3):419-23. PubMed ID: 2012769
[TBL] [Abstract][Full Text] [Related]
2. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis.
Mohr B; Herrmann R; Huhn D
Acta Haematol; 1993; 90(2):65-70. PubMed ID: 8285020
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes.
Ghio R; Balleari E; Ballestrero A; Gatti AM; Mareni C; Massa G; Patrone F; Sessarego M; Timitilli S
Acta Haematol; 1993; 90(2):58-64. PubMed ID: 8285019
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment.
Verhoef GE; Zachée P; Ferrant A; Demuynck H; Selleslag D; Van Hove L; Deckers F; Boogaerts MA
Ann Hematol; 1992 Jan; 64(1):16-21. PubMed ID: 1739754
[TBL] [Abstract][Full Text] [Related]
6. High-dose recombinant human erythropoietin administered intravenously for the treatment of anaemia in myelodysplastic syndromes.
Casadevall N; Belanger C; Goy A; Varet B; Lang J; Poisson D
Acta Haematol; 1992; 87 Suppl 1():25-7. PubMed ID: 1574964
[TBL] [Abstract][Full Text] [Related]
7. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
8. [Human recombinant erythropoietin in the treatment of myelodysplastic syndromes anemia. Meta-analytic study].
Rodríguez JN; Diéguez JC; Muñiz R; Martino ML; Fernández-Jurado A; Amian A; Cañavate M; Prados D
Sangre (Barc); 1994 Dec; 39(6):435-9. PubMed ID: 7855695
[TBL] [Abstract][Full Text] [Related]
9. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS).
Rose EH; Abels RI; Nelson RA; McCullough DM; Lessin L
Br J Haematol; 1995 Apr; 89(4):831-7. PubMed ID: 7772519
[TBL] [Abstract][Full Text] [Related]
10. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin.
Economopoulos T; Mellou S; Papageorgiou E; Pappa V; Kokkinou V; Stathopoulou E; Pappa M; Raptis S
Leukemia; 1999 Jul; 13(7):1009-12. PubMed ID: 10400415
[TBL] [Abstract][Full Text] [Related]
11. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.
Wallvik J; Stenke L; Bernell P; Nordahl G; Hippe E; Hast R
Eur J Haematol; 2002 Mar; 68(3):180-5. PubMed ID: 12068800
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of recombinant human erythropoietin (rhuEPO) in treatment of anemia in patients with myelodysplastic syndrome].
Wiecek A; Chudek J; Nieszporek T; Kokot F
Pol Arch Med Wewn; 1992 Dec; 88(6):451-7. PubMed ID: 1300567
[TBL] [Abstract][Full Text] [Related]
13. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
[TBL] [Abstract][Full Text] [Related]
14. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia.
Bessho M; Jinnai I; Matsuda A; Saito M; Hirashima K
Int J Cell Cloning; 1990 Nov; 8(6):445-58. PubMed ID: 2273298
[TBL] [Abstract][Full Text] [Related]
15. Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia.
van Kamp H; Prinsze-Postema TC; Kluin PM; den Ottolander GJ; Beverstock GC; Willemze R; Fibbe WE
Br J Haematol; 1991 Aug; 78(4):488-93. PubMed ID: 1911340
[TBL] [Abstract][Full Text] [Related]
16. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model.
Hellström-Lindberg E; Negrin R; Stein R; Krantz S; Lindberg G; Vardiman J; Ost A; Greenberg P
Br J Haematol; 1997 Nov; 99(2):344-51. PubMed ID: 9375752
[TBL] [Abstract][Full Text] [Related]
17. Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment.
Yoshida Y; Anzai N; Kawabata H; Kohsaka Y; Okuma M
Ann Hematol; 1993 Apr; 66(4):175-80. PubMed ID: 8485205
[TBL] [Abstract][Full Text] [Related]
18. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome.
Goy A; Belanger C; Casadevall N; Picard F; Guesnu M; Jaulmes D; Poisson D; Varet B
Br J Haematol; 1993 Jun; 84(2):232-7. PubMed ID: 8398823
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human erythropoietin in the treatment of cancer-related anaemia.
Kasper C; Terhaar A; Fosså A; Welt A; Seeber S; Nowrousian MR
Eur J Haematol; 1997 Apr; 58(4):251-6. PubMed ID: 9186536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
